• Ascentage Pharma highlighted 17 clinical updates already presented at the 2026 EHA meeting in Stockholm held June 11-14.
• Olverembatinib data supported durable responses in chronic myeloid leukemia, including patients resistant or intolerant to prior TKIs.
• A prospective study favored switching to olverembatinib over continuing prior TKIs, supporting its positioning as a standard option in later-line CML.
• In newly diagnosed Ph+ ALL, a global Phase III program showed deep remissions with manageable safety, reinforcing first-line registration prospects.
• A chemotherapy-free oral combination of olverembatinib with lisaftoclax showed rapid, deep responses in pediatric relapsed or refractory Ph+ ALL.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260615-12201874), on June 14, 2026, and is solely responsible for the information contained therein.